ORIC Pharmaceuticals To Present Initial Phase 1b Clinical Data For ORIC 114 In EGFR/HER2 Exon 20 Mutated NSCLC At The European Society Of Medical Oncology Congress 2023
Portfolio Pulse from Benzinga Newsdesk
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) will present two poster presentations at the European Society of Medical Oncology (ESMO) Congress 2023. The presentations will highlight the initial Phase 1b clinical data for ORIC-114 in EGFR/HER2 exon 20 mutated cancers and new preclinical data for ORIC-114 demonstrating activity against additional atypical mutations in EGFR. A conference call and webcast will be hosted by ORIC on October 21, 2023.
October 17, 2023 | 8:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ORIC Pharmaceuticals will present initial Phase 1b clinical data for ORIC-114 at the ESMO Congress 2023, which could potentially impact the company's stock.
The presentation of initial Phase 1b clinical data for ORIC-114 at a major medical congress could potentially influence investor sentiment and impact ORIC's stock. The data could provide insights into the potential efficacy of the drug, which could in turn affect the company's future revenue prospects.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100